ArticleNPJ precision oncology2025
Pan cancer research reveals the role of PTGDS in tumor suppression and immune regulation.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The Burden of Breast Cancer and its Attributable Risk Factors in 204 Countries and Territories, 1990-2021: Results From the Global Burden of Disease Study 2021.Cancer innovation · 2026Article
- Exploration of precise classification and therapeutic targets of breast cancer based on genes related to neuro-cancer crosstalk.Translational oncology · 2026Article
- Artificial-intelligence- and multi-omics-guided predictive and drug repurposing framework construction for colorectal cancer: evidence from succinylation-neutrophil signatures.Frontiers in cell and developmental biology · 2026Article
- Integrated multi-omics characterization of SPTBN2 overexpression reveals its pro-tumorigenic role and immune microenvironment remodeling in colorectal cancer.Frontiers in cell and developmental biology · 2026Article
- SIRT2 is associated with prognosis, ferroptosis susceptibility, and immune infiltration in lung adenocarcinoma.Frontiers in oncology · 2026Article
- Advances in protein ubiquitination modification and immune evasion of breast cancer.Frontiers in cell and developmental biology · 2026Review
- Macrophage-associated prognostic modeling uncovers immunotherapy response mechanisms and defines HAGHL as a novel oncogenic driver in breast cancer.Frontiers in immunology · 2026Article
- Multi-omics analysis of ST3GAL4-mediated lacto/neolacto glycosphingolipid metabolism reveals immune evasion and poor prognosis in TNBC.Frontiers in immunology · 2026Article
- Low PTGDS Expression Facilitates HNSCC by Suppressing Programmed Cell Death and Reducing B Cell-Mediated Immune Responses.Mediators of inflammation · 2026Article
- Identification of endogenous reference genes for RT-qPCR analysis in breast cancer and matched adjacent tissues.Frontiers in oncology · 2025Article
- PELI1 in human cancers: a pan-cancer exploration of its molecular function, clinical significance, and immunomodulatory roles.Frontiers in immunology · 2025Article
- A multi-omic machine learning approach deconstructs the role of amino acid metabolism in the immune microenvironment and prognosis of colon adenocarcinoma.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Prostaglandin D2 synthase (PTGDS), a newly identified anti-tumor target, shows promise in inhibiting various cancers and plays significant roles in the tumor microenvironment and immune regulation, yet a comprehensive pan-cancer analysis of its expression and prognostic value remains lacking. This study used multi-omics data from public databases to assess PTGDS's expression, mutation, and modification in multiple cancers, integrated single-cell and spatial transcriptomic data to explore its relationship with immune cells, and conducted in vitro and in vivo experiments in breast cancer (BRCA). Results showed that PTGDS is significantly dysregulated in most cancers, with its expression associated with different outcomes depending on cancer type. It correlates with epigenetic and biological functions, and low expression in BRCA indicates poor prognosis. Overexpression of PTGDS can inhibit breast cancer cell proliferation and invasion, increase CD8+ T - cell activity, and enhance anti-tumor immunity. Combining it with anti-PD-L1 improves BRCA treatment. PTGDS is a potential prognostic biomarker and a novel immunotherapy target for BRCA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.